Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: Findings from a noninferiority trial

Ulf Harnest, David Price, Tim Howes, Gordon Sussman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. Inhaled corticosteroids (ICSs) are one of the suggested first-line therapies for patients with persistent asthma of moderate severity. Methods: The efficacy and safety of mometasone furoate (MF) 400 mu g twice daily (BID) and fluticasone propionate (FP) 500 mu g BID administered for 12 weeks via dry powder inhaler (DPI) were compared in a noninferiority trial, in adults with moderate-to-severe persistent asthma. The primary variable was the change from baseline in AM peak expiratory flow rate (PEFR). Pm PEFR, forced expiratory volume in 1 second (FEV1), asthma symptoms, rescue medication use, response to therapy, exacerbation rates, and adverse events were also assessed. Results. The lower bound of 95% CIs for treatment differences in the primary variable ranged from 2.6% to 5.6% throughout the 12-week study and were within the prespecified noninferiority range. No significant between-group differences were observed in lung function, rescue medication use, response to therapy, exacerbation rates, or adverse events. At most of the weeks assessed, there were no between-group differences in asthma symptoms. Most adverse events were mild-to-moderate. Conclusion. MF-DPI 400 mu g BID was therapeutically equivalent to FP-DPI 500 mu g BID in patients with moderate-to-severe persistent asthma.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalJournal of Asthma
Volume45
Issue number3
DOIs
Publication statusPublished - 2008

Keywords

  • asthma
  • fluticasone propionate
  • mometasone furoate
  • noninferiority trial
  • beta(2)-agonist
  • pituitary-adrenal axis
  • efficacy
  • safety
  • suppression

Fingerprint

Dive into the research topics of 'Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: Findings from a noninferiority trial'. Together they form a unique fingerprint.

Cite this